Searched for
ANTI OBESITY PILLS
India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...- Ahead of its time, a GLP-1 drug almost made it out of IndiaFifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes man...
- Novo Nordisk cuts price for Ozempic, Wegovy. How much weight-loss, anti-obesity, diabetes medicines will cost?Wegovy and Ozempic price cuts will be effective January 1 next year, coinciding with the implementation of new, lower prices for the same ...
- Take a pill! Novo Nordisk's Wegovy gets US' nod as daily pill for obesity treatmentNovo Nordisk's popular weight-loss drug Wegovy is now available as a pill in the US. The US Food and Drug Administration has approved the o...
- What is Ozempic 2.0? Is it the future of weight loss? Here's what you need to know about the new drugA new pill, Orforglipron, is set to revolutionize weight loss and diabetes treatment. This daily pill, developed by Eli Lilly, has shown si...
- Soon, take your pick of more OzempicsA crucial ingredient in weight loss drugs will become available as generics next year in India and other major markets. This is expected to...
- Novo Nordisk's Wegovy, Mounjaro sales in India double on month in JulySales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, launched in June, s...
- Obesity drugs gain weight in labs: Several clinical trials by big and small pharma cos underwayDriven by the success of Wegovy and Mounjaro, numerous pharma companies are developing anti-obesity drugs, with over 170 in various stages....
- Eli Lilly says its anti-obesity pill matches OzempicEli Lilly's Orforglipron, an anti-obesity pill, demonstrated significant weight loss and blood sugar reduction in clinical trials, rivaling...
- India's anti-obesity drug market has grown more than fourfold in the last five yearsIndia's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle di...
- India’s anti-obesity drug market quadruples in five years on lifestyle disease surgeIndia's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025. Semaglutide pill Ryb...
- Ozempic frenzy lures rich Indians to brave the gray marketPeople are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying coun...
- New oral diabetes + obesity drug's India sales surge 100%India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenge...
- Weight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivotWeight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in gen...
- Eli Lilly in advanced clinical trials for its weight-loss pillEli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess ...
- Novo Nordisk launches anti-diabetes pill semaglutide in IndiaNovo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in India for treatment of type 2 diabetes.
- Herbal slimming pills are harmful: Consumer Education & Research CenterChanging lifestyle, lack of time for exercise and inability to control the desire for unhealthy food has proved boon for fat fighting solut...
- Centre bans anti-obesity drug due to side effectsThe government has banned manufacturing and sale of anti-obesity medicine Sibutramine and its combination drugs sold under various brands d...
- Govt may ban anti-obesity drug fearing side-effectsSlimona, Obitone and Riobant, the money-spinning drug that was launched just two years ago in India, allegedly causes suicidal tendencies i...
- DRL’s anti-diabetes drug to hit market by ’11Dr Reddy’s anti-diabetes molecule Balaglitazone, which has entered the final phase of clinical development, is expected to hit the world ma...
Load More
